Gilad Mamlok - 24 Aug 2025 Form 3 Insider Report for Protalix BioTherapeutics, Inc. (PLX)

Role
Sr. VP and CFO
Signature
/s/ Gilad Mamlok
Issuer symbol
PLX
Transactions as of
24 Aug 2025
Net transactions value
$0
Form type
3
Filing time
25 Aug 2025, 16:31:42 UTC
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Mamlok Gilad Sr. VP and CFO CO PROTALIX BIOTHERAPEUTICS, INC., CARMIEL, ISRAEL /s/ Gilad Mamlok 25 Aug 2025 0001975896

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding PLX Stock Option (Right to Buy) 24 Aug 2025 Common Stock 597,990 $1.45 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares of common stock underlying the stock options shall vest in 12 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended.